

Remarks

Claims 1, 5, 13, 16-18, 22-23, 30, 43-46, 49, 51, 53, 55-57, 59, 63, 68-71, 87-90 and 92-118 were allowed in the Notice of Allowance mailed May 23, 2002.

As it is believed that no new matter has been added by the above amendments to claims 23, 44, 45, 46, 49, 51, 53, 55 and 102, entry and consideration of this amendment is respectfully requested.

A Marked Up copy of the amended claims is appended to this amendment as required by 37 C.F.R. §1.121.

Applicants also submit with this Amendment a Petition To Correct Inventorship Under 37 C.F.R. 1.48 (b) requesting deletion of inventors Janos Tibor Kodra and Anker Steen Jorgensen from the above-captioned patent application.


As stated in the accompanying Petition Under 37 C.F.R. 1.48 (b), the correct inventors were named in the application when filed. However, the prosecution of the application has resulted in the amendment and cancellation of claims so that less than all of the originally named inventors are the actual inventors of the invention being claimed in the application.

Applicants therefore have deleted Janos Tibor Kodra and Anker Steen Jorgensen as inventors.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: August 23, 2002


  
\_\_\_\_\_  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650  
PATENT TRADEMARK OFFICE


"Marked-Up" Copy Of Amended Claims

23. (Amended) A compound according to claim 22, wherein D is




wherein R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are as defined in claim 1].

44. (Amended) A compound according to claim 43, wherein E is




[wherein m, p and  $R^{23}$  to  $R^{35}$  are as defined in claim 1].

45. (Amended) A compound according to claim 44, wherein E is




[wherein p, R<sup>23</sup>, R<sup>24</sup>, R<sup>25</sup>, R<sup>26</sup>, R<sup>27</sup>, R<sup>28</sup>, R<sup>29</sup>, R<sup>30</sup>, R<sup>34</sup> and R<sup>35</sup> are as defined in claim 1].

46. (Amended) A compound according to claim 45, wherein E is



wherein R<sup>23</sup>, R<sup>24</sup>, R<sup>25</sup>, R<sup>26</sup>, R<sup>27</sup>, R<sup>34</sup> and R<sup>35</sup> are as defined in claim 1].


49. (Amended) A compound according to claim 45, wherein E is



wherein R<sup>23</sup> and R<sup>24</sup> are as defined in claim 1].

51. (Amended) A compound according to claim 49, wherein R<sup>23</sup> and R<sup>24</sup> independently are selected from hydrogen, C<sub>1-6</sub>-alkyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkylidene, phenoxy, phenyl, -C(O)NR<sup>36</sup>R<sup>37</sup> and -OC(O)NH-phenyl, of which the phenyl moiety optionally may be substituted with -OCF<sub>3</sub>, [wherein R<sup>36</sup> and R<sup>37</sup> are as defined in claim 1,] or R<sup>23</sup> and R<sup>24</sup> together form the radical -(CH<sub>2</sub>)<sub>t</sub>-CR<sup>40</sup>R<sup>41</sup>-(CH<sub>2</sub>)<sub>l</sub>-, -O-(CH<sub>2</sub>)<sub>t</sub>-CR<sup>40</sup>R<sup>41</sup>-(CH<sub>2</sub>)<sub>l</sub>-O-, -S-(CH<sub>2</sub>)<sub>t</sub>-CR<sup>40</sup>R<sup>41</sup>-(CH<sub>2</sub>)<sub>l</sub>-S-, wherein t, l, R<sup>40</sup> and R<sup>41</sup> are as defined in claim 1].


53. (Amended) A compound according to claim 46, wherein E is



wherein R<sup>25</sup>, R<sup>26</sup> and R<sup>27</sup> are as defined in claim 1].

55. (Amended) A compound according to claim 53, wherein R<sup>25</sup>, R<sup>26</sup> and R<sup>27</sup> independently are selected from hydrogen, halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy, C<sub>3-8</sub>-cycloalkyl, C<sub>4-8</sub>-cycloalkenyl, -CF<sub>3</sub>, -OCF<sub>3</sub> or -NR<sup>42</sup>R<sup>43</sup>, [wherein R<sup>42</sup> and R<sup>43</sup> are as defined in claim 1].

102. (Amended) A compound according to claim 23, wherein D is



[wherein R<sup>16</sup>, R<sup>17</sup> and R<sup>18</sup> are as defined in claim 1].